Company Filing History:
1 out of 30 
1 out of 49 
1 out of 2 Years Active: 2015-2025
Title: Antonio Pezzutto: Innovator in Immunotherapy
Introduction
Antonio Pezzutto is a prominent inventor based in Berlin, Germany. He has made significant contributions to the field of immunotherapy, particularly in the development of T cell therapies for cancer treatment. With a total of 3 patents, his work focuses on innovative approaches to combat B cell malignancies.
Latest Patents
Pezzutto's latest patents include groundbreaking inventions such as CD22-specific T cell receptors and adoptive T cell therapy for the treatment of B cell malignancies. This invention is directed towards immunotherapy, specifically targeting B cell lymphoma and leukemia. It provides a nucleic acid encoding T cell receptor (TCR) constructs capable of binding to the CD22 antigen, leading to the lysis of CD22-positive cells. Another notable patent involves specific T cell receptors against epitopes of the mutant MYD88L265P protein, which are utilized in adoptive T cell therapies for various cancers, including non-Hodgkin B-cell lymphoma.
Career Highlights
Throughout his career, Antonio Pezzutto has worked with esteemed institutions such as the Max Delbrück Center for Molecular Medicine and Charité-Universitätsmedizin Berlin. His research has significantly advanced the understanding and treatment of cancer through innovative immunotherapeutic strategies.
Collaborations
Pezzutto has collaborated with notable colleagues, including Oliver Schmetzer and Özcan Cinar, contributing to the advancement of cancer therapies.
Conclusion
Antonio Pezzutto's contributions to immunotherapy exemplify the impact of innovative thinking in the medical field. His patents and research continue to pave the way for new treatment options for patients suffering from B cell malignancies.